Text Size: a  |   a 

AAN Meeting: Ocrevus Data Support Sustained Efficacy, Ability to Aid Cognition in RMS Patients

April 20, 2018

Treatment with Ocrevus (ocrelizumab) shows sustained efficacy and an ability to improve cognition in patients with relapsing multiple sclerosis (MS), according to data being presented by Genentech, the drug’s developer.

The company will detail these findings in a series of oral and poster sessions at the 2018 American Academy of Neurology (AAN) Annual Meeting, opening Saturday and running through April 27 in Los Angeles.

For a first time, Genentech will also present data regarding the impact of the therapy on biomarkers of inflammation and neurodegeneration in RMS patients, as assessed through the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Phase 3 study (NCT02688985).

Previous results of the OBOE trial in these patients patients showed that Ocrevus worked to lower the levels of cerebrospinal fluid biomarkers that reflect nerve cell damage.

The trial also includes primary progressive MS patients and is currently recruiting participants (for more information about trial participation, please visit this link). The company expects to have final results early in 2019.
READ MORE via MS News Today